Travere Therapeutics' Cash from Operations rose 133.68% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.6 million, marking a year-over-year increase of 77.98%. This contributed to the annual value of -$237.5 million for FY2024, which is 27.01% up from last year.
Travere Therapeutics' Cash from Operations amounted to $14.3 million in Q3 2025, which was up 187.32% from $5.0 million recorded in Q2 2025.
Over the past 5 years, Travere Therapeutics' Cash from Operations peaked at $32.1 million during Q3 2021, and registered a low of -$119.0 million during Q1 2024.
For the 3-year period, Travere Therapeutics' Cash from Operations averaged around -$53.2 million, with its median value being -$42.5 million (2024).
As far as peak fluctuations go, Travere Therapeutics' Cash from Operations surged by 376.07% in 2021, and later tumbled by 666.59% in 2022.
Travere Therapeutics' Cash from Operations (Quarterly) stood at -$88.3 million in 2021, then climbed by 13.16% to -$76.7 million in 2022, then rose by 16.08% to -$64.4 million in 2023, then soared by 44.51% to -$35.7 million in 2024, then spiked by 133.68% to $14.3 million in 2025.
Its Cash from Operations stands at $14.3 million for Q3 2025, versus $5.0 million for Q2 2025 and -$42.2 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value